Valuation: Monopar Therapeutics Inc.

Market Cap 651M 570M 525M 487M 925M 62.06B 938M 6.28B 2.44B 30.46B 2.44B 2.39B 106B P/E 2026 *
-42.1x
P/E 2027 * -28x
Enterprise Value 532M 466M 429M 398M 756M 50.75B 767M 5.14B 2B 24.91B 2B 1.95B 86.37B EV / Sales 2026 *
-
EV / Sales 2027 * 34x
Free-Float
76.77%
Yield 2026 *
-
Yield 2027 * -
1 day+0.75%
1 week+4.80%
Current month+4.80%
1 month+60.10%
3 months+81.00%
6 months+49.26%
Current year+48.60%
1 week 93.59
Extreme 93.59
101.09
1 month 58.01
Extreme 58.01
101.09
Current year 50.07
Extreme 50.07
101.09
1 year 29.18
Extreme 29.18
105
3 years 1.37
Extreme 1.3695
105
5 years 1.37
Extreme 1.3695
105
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 30/11/2014
Director of Finance/CFO 54 02/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 30/11/2014
Chairman 73 30/11/2014
Director/Board Member 84 31/03/2017
Date Insider Type Main position Quantity % Market Cap.
06-29Fiscal year

Chief Operating Officer

12,817 0.1913%
06-29Fiscal year

Founder

29,830 0.4453%
06-29Fiscal year

Chief Financial Officer

2,963 0.0442%
Change 5-day change 1-year change 3-year change Capi.($)
+0.56%+4.80%+160.85%+2,304.83% 651M
-1.03%+5.68%+3.37%+9.87% 50.25B
+0.03%+0.93%+415.46%+616.26% 40.39B
+1.00%+7.47%+27.83%-4.22% 34.38B
-1.25%+7.44%+27.04%+61.52% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+1.97%+2.37% - - 16.64B
-3.07%+3.87%+72.50%+133.56% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+2.82%+7.76%+104.51%+104.51% 13.75B
Average +0.29%+3.54%+92.34%+364.63% 24.66B
Weighted average by Cap. +0.04%+4.10%+95.13%+146.25%

Financials

2026 *2027 *
Net sales - 15.85M 13.88M 12.79M 11.87M 22.54M 1.51B 22.84M 153M 59.56M 742M 59.52M 58.21M 2.57B
Net income -20.16M -17.66M -16.26M -15.1M -28.67M -1.92B -29.05M -195M -75.76M -944M -75.71M -74.05M -3.27B -35.78M -31.33M -28.86M -26.79M -50.87M -3.41B -51.56M -345M -134M -1.68B -134M -131M -5.81B
Net Debt -119M -104M -95.64M -88.78M -169M -11.31B -171M -1.14B -446M -5.55B -445M -435M -19.25B -112M -98.39M -90.62M -84.11M -160M -10.72B -162M -1.08B -422M -5.26B -422M -413M -18.24B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
07/07/26 US$97.04 -0.09% 63,181
06/07/26 US$97.12 -0.69% 103,870
02/07/26 US$97.79 +2.90% 188,267
01/07/26 US$95.03 +2.64% 177,531
30/06/26 US$92.59 -2.08% 111,800
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
97.12USD
Average target price
113.62USD
Spread / Average Target
+16.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock